Comparing the current results to its competitors, Maxcyte Inc reported Revenue decrease in the 2 quarter 2026 year on year by -14.53 %, despite the revenue increase by the most of its competitors of 1.37 %, recorded in the same quarter.
Maxcyte Inc 's Comment on Competition and Industry Peers
The company utilizes its proprietary ExPERT platform to deliver a wide range of molecules into various cell types, supported by a comprehensive intellectual property portfolio and proprietary expertise. Competitors in the electroporation and non-viral delivery technology sectors include Lonza Group AG, Thermo Fisher Scientific Inc., Miltenyi Biotec, Bio-Rad Laboratories, Inc., Harvard Biosciences Inc., as well as several smaller firms and academic spinouts. Some competitors possess greater financial resources, larger research and development teams, or more established sales operations. The company employs a layered intellectual property strategy that incorporates patents, proprietary knowledge, and trade secrets to maintain its competitive position.
September 16, 2024
In an ambitious stride toward transforming the landscape of genetic disease treatment, MaxCyte Inc. a global leader in cell engineering and therapeutic research, has entered into a strategic platform license agreement with Kamau Therapeutics. This collaboration aims to harness MaxCyte’s sophisticated Flow Electroporation technology and ExPERT platform to bolster Kamau s pioneering homology-directed repair (HDR) gene correction technology. Unpacking the Strategic PartnershipThe strategic platform license forged between MaxCyte and Kamau Therapeutics is set to empower Kamau in its quest to innovate and expedite the development of cell-based therapies targeting complex genetic disorders. MaxCyte’s Flow Elec...
January 3, 2024
MaxCyte Inc., a leading global company specialized in scalable high-performance cell engineering, and Lion TCR, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR) T cell therapies, have recently announced a strategic partnership. This union aims to bolster the global expansion of Lion TCR s TCR-T cell pipeline, a groundbreaking therapeutic strategy that leverages the body s immune cells to combat various diseases including solid tumors and viral-related diseases.This collaboration comes at a time when the TCR-T cell therapy market is expanding rapidly due to its revolutionary approach to treatment. The technology utilizes T cells extracted from each patient s blood, wh...
Omniab Inc is a technology company that operates on a B2B (business-to-business) model, offering a range of software solutions and services. The company focuses on providing customized software applications to help businesses streamline their operations, enhance productivity, and improve efficiency. Omniab Inc also offers consultation services to assist companies in optimizing their IT infrastructure.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Sources:
Maxcyte inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Maxcyte inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
